pharmaphorum

MARCH 6, 2024

A £650 million investment package by AstraZeneca in the UK has been held up by Chancellor Jeremy Hunt as a “vote of confidence” in the country’s life sciences sector.

Packaging 110

Packaging Vaccines 110

Drug Topics

MARCH 18, 2024

AstraZeneca is the second pharmaceutical company to cap out-of-pocket costs for eligible patients.

Pharmaceutical Companies 144

Pharmaceutical Companies Pharmaceutical Companies 144

STAT

MARCH 14, 2024

LONDON —   AstraZeneca said Thursday it would purchase the French firm Amolyt Pharma in a deal worth up to $1 billion, picking up a rare disease drug in a pivotal trial.   AstraZeneca framed the deal for Amolyt, which has focused on treatments for rare endocrine diseases, as a boost for its own rare disease pipeline.

123

123

STAT

MARCH 19, 2024

LONDON — AstraZeneca said Tuesday it would acquire Fusion Pharmaceuticals in a deal worth more than $2 billion, picking up a company focused on the booming area of targeted radiation therapies for cancer. If certain regulatory milestones are met, AstraZeneca will pay another $3 a share, or roughly $400 million.

136

136

Fierce Pharma

APRIL 1, 2024

With AstraZeneca’s dominance in the rare blood disease paroxysmal nocturnal hemoglobinuria (PNH) threatened by the recent approval of the first pill on the market for the condition, Novartis’ Fabha | With AstraZeneca’s dominance in the rare blood disease paroxysmal nocturnal hemoglobinuria (PNH) threatened by the recent approval of the first pill on (..)

FDA 110

FDA 110

pharmaphorum

MARCH 28, 2024

Explore the case study on MHRA and AstraZeneca's camizestrant, a Selective Estrogen Receptor Degrader (SERD) for breast cancer treatment. Learn about the regulatory journey and success of this innovative therapy.

71

71

Pharmacy Times

APRIL 2, 2024

The Asthma and Allergy Foundation of America applauded the efforts by AstraZeneca, saying accessibility and affordability can help reduce racial disparities in asthma.

111

111

STAT

MARCH 1, 2024

WASHINGTON — A federal judge in Delaware on Friday ruled against AstraZeneca in a case challenging the constitutionality of Medicare’s new drug price negotiation program. Colm Connolly, chief judge of the U.S. District Court of Delaware, ruled against the company on all its major arguments.

115

115

Pharmaceutical Technology

APRIL 26, 2024

AstraZeneca has reported profit after tax of $2.18bn for the first quarter (Q1) of 2024, a notable rise from $1.80bn reported in the same period last year.

52

52

Fierce Pharma

FEBRUARY 6, 2024

Following a slew of cell therapy biotech team-ups, AstraZeneca is taking manufacturing into its own hands. AstraZeneca is plugging $300 million into a new facility in Rockville, Maryland, to launch its cell therapy platforms in the United States for cancer trials and future commercial supply.

129

129

Fierce Pharma

JANUARY 2, 2024

AstraZeneca and Sanofi have scored first in | AstraZeneca and Sanofi have scored first in China with an approval for their respiratory syncytial virus (RSV) immunization Beyfortus for infants, with the companies expecting the shot to be available there for the 2024-25 season.

Immunization 115

Immunization 115

Pharmafile

NOVEMBER 1, 2023

AstraZeneca has announced a collaboration and investment agreement with Cellectis for the development of next generation cell and gene therapeutics (CGTs) in areas such as oncology, immunology and rare diseases.

116

116

Fierce Pharma

FEBRUARY 20, 2024

AstraZeneca, having surpassed its long-term $45 billion revenue goal last year, has handsomely rewarded its chief executive. AstraZeneca CEO Pascal Soriot’s compensation package makes him the current top contender for 2023’s highest-paid pharma CEO in Europe.

Packaging 118

Packaging 118

Fierce Pharma

FEBRUARY 8, 2024

billion in 2023 revenues, AstraZeneca has met the $45 billion-by-2023 goal CEO Pascal Soriot established in 2014 when he was fending off a takeover bid from Pfizer. AstraZeneca has met the $45 billion-by-2023 revenue goal that CEO Pascal Soriot established in 2014.

127

127

Pharmafile

MARCH 19, 2024

AstraZeneca has announced that it has entered into a definitive agreement to acquire Fusion Pharmaceuticals for an approximate $2bn. Fusion Pharmaceuticals has a […] The post AstraZeneca to acquire Fusion for approximately $2bn appeared first on Pharmafile.

Chemotherapy 59

Chemotherapy 59

Fierce Pharma

MARCH 1, 2024

Less than three weeks after a Texas judge tossed a lawsuit b | Less than three weeks after a Texas judge tossed a lawsuit by industry lobbying group PhRMA that challenged the constitutionality of the Inflation Reduction Act, a federal court in Delaware has done the same with a similar action brought by AstraZeneca.

112

112

European Pharmaceutical Review

JANUARY 2, 2024

billion, AstraZeneca has agreed to acquire Gracell Biotechnologies, supporting the development of cell therapies in haematology and autoimmune diseases. The cell therapy also has potential in other haematologic malignancies, as well as autoimmune diseases including systemic lupus erythematosus (SLE), AstraZeneca highlighted.

Immunization 86

Immunization 86

Outsourcing Pharma

APRIL 15, 2024

AstraZeneca's latest modelling analysis, IMPACT CKD, presented at the 2024 ISN World Congress of Nephrology (WCN'24) in Buenos Aires, paints a concerning picture of the future of chronic kidney disease (CKD) across eight countries.

79

79

Fierce Pharma

JANUARY 31, 2024

AstraZeneca-partnered Enhertu has become a bright spot in Daiichi Sankyo’s business, and the Japanese pharma has again increased its sales projection for the HER2-directed antibody-drug conjugate.<

110

110

European Pharmaceutical Review

FEBRUARY 7, 2024

AstraZeneca has announced a $300 million investment in a US-based manufacturing facility in Rockville, Maryland, which will focus initially on T-cell therapies for oncology indications. The site may widen its focus to support other disease areas, according to AstraZeneca.

88

88

STAT

MARCH 27, 2024

AstraZeneca filed a lawsuit seeking to block an Arkansas law that requires the company to ship its medicines to any pharmacy working with hospitals participating in a controversial federal discount program. As a result, AstraZeneca argued the law is illegal because it is preempted by federal law and also violates the U.S. Constitution.

Hospitals 101

Hospitals Pharmaceutical Companies Pharmaceutical Companies 101

Pharmafile

MARCH 14, 2024

AstraZeneca has announced that it has entered into a definitive agreement under which it will acquire Amolyt Pharma for up to $1.05bn, with the focus on adding to AstraZeneca’s Alexion’s rare diseases pipeline.

64

64

STAT

DECEMBER 21, 2023

The drug, from partners AstraZeneca and Ionis Pharmaceuticals, is a monthly injection for a genetic disorder called ATTR-PN, in which a buildup of toxic bodily proteins progressively damages patients’ peripheral nerves.

FDA 123

FDA 123

Pharmaceutical Technology

FEBRUARY 9, 2024

AstraZeneca has reported a significant 81% rise in profit after tax, reaching $5.96bn for FY 2023 from $3.29bn in the previous year.

105

105

Pharmaceutical Technology

FEBRUARY 7, 2024

AstraZeneca is investing $300m in a facility in Rockville, US - a significant step in launching its cell therapy platforms in the country.

97

97

Fierce Pharma

MARCH 18, 2024

And AstraZeneca, utilizing a similar immunotherapy strategy, has also come up with a rivaling update as it awaits an FDA decision. . | After a quick FDA approval in a subset of endometrial cancer, GSK is back with more data for two Jemperli regimens—including one with a PARP drug—in hopes of reaching a broader patient population.

FDA 113

FDA 113

Fierce Pharma

OCTOBER 3, 2023

Four months after GSK settled a key case in California over its heartburn medication Zantac, AstraZeneca is following suit, agreeing to resolve personal injury claims over its heartburn drugs Nexiu | Four months after GSK settled a key case in California over its heartburn medication Zantac, AstraZeneca is following suit, agreeing to resolve personal (..)

118

118

pharmaphorum

NOVEMBER 23, 2023

AstraZeneca joins KRAS push in cancer with Chinese deal Phil.Taylor Thu, 23/11/2023 - 16:46 Bookmark this

129

129

Pharmafile

APRIL 5, 2024

AstraZeneca has announced positive high-level results from the phase 3 ADRIATIC trial, which demonstrated that Imfinzi (durvalumab) had a statistically significant and clinically meaningful improvement in the dual primary endpoints of overall survival (OS) and progression-free survival (PFS) in patients with limited-stage small cell lung cancer (LS-SCLC) (..)

64

64

Fierce Pharma

MARCH 21, 2024

The drugmaker's commitment will start by January 1, 2025, and follows similar moves by peers Boehringer Ingelheim and AstraZeneca. Amid congressional scrutiny on U.S. | Before the pledges, the companies—and Teva—caught Senate heat over high U.S. inhaler prices.

105

105

PharmaVoice

NOVEMBER 16, 2023

conducted a study with AstraZeneca showing the alarming extent to which immunocompromised patients are burdened with COVID-19. Paul Moss, a hematology expert in the U.K.,

116

116

The Guardian - Pharmaceutical Industry

APRIL 11, 2024

pay boost Shareholders at AstraZeneca are in line for a 7% increase in dividends this year as the pharmaceutical company attempts to garner support for a pay deal worth up to £19m for its boss, Pascal Soriot. AstraZeneca said it intended to increase the annual dividend for 2024 by $0.20

Pharmaceutical Companies 58

Pharmaceutical Companies Pharmaceutical Companies 58

Pharmafile

APRIL 2, 2024

The US Food and Drug Administration […] The post FDA accepts BLA for AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan for breast cancer treatment appeared first on Pharmafile.

FDA 64

FDA 64

Pharmafile

JANUARY 2, 2024

AstraZeneca and Sanofi have announced that Beyfortus (nirsevimab) has been approved in China for the prevention of respiratory syncytial virus (RSV) lower respiratory tract infection and disease (LRTI and LRTD) in neonates and infants entering or during their first RSV season.

64

64

Fierce Pharma

JUNE 4, 2023

AstraZeneca and Daiichi Sankyo’s Enhertu has already made waves in breast cancer treatment. AstraZeneca and Daiichi Sankyo’s Enhertu has already made waves in breast cancer treatment.

133

133

Pharmafile

NOVEMBER 21, 2023

AstraZeneca has announced that it has launched Evinova, its new health-tech business, which it is hoped will become a leading provider of digital health solutions for healthcare professionals, regulators and patients.

59

59

Fierce Pharma

NOVEMBER 17, 2023

Amid a corporate review of AstraZeneca’s global manufacturing and supply network, the company’s Indian subsidiary is planning to close up shop at the “beating heart” of its India operations in Bang | AstraZeneca Pharma India will exit its production plant in Bangalore, India, “in due course,” the company said in a filing.

124

124